About Kintara Therapeutics

About Kintara Therapeutics

Kintara Therapeutics is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a first-in-class small molecule chemotherapy that is currently being evaluated in a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.

We have acquired certain exclusive commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer.

Learn More about Kintara Therapeutics

About the Clinical Trials

VAL-083 is a structurally unique, "first-in- class", small-molecule chemotherapeutic. Based on historical data and our own research, we believe that VAL-083 has the potential to offer physicians and patients a new paradigm in the treatment of Glioblastoma Multiforme (GBM).

The purpose of this Phase 2, open-label, single-arm study is to determine the safety and the

For Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression: More Information

The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and

For Patients With Recurrent Malignant Glioma: More Information